Navigation Links
Angelica Therapeutics Receives a $244,479 Qualified Therapeutic Discovery Project Grant for Its Anti-Cancer Drug
Date:12/9/2010

EMERYVILLE, Calif., Dec. 9, 2010 /PRNewswire/ -- Angelica Therapeutics, Inc., a privately held drug development company focused on the development and commercialization of therapeutics incorporating novel nonimmunogenic fusion toxins, announced that it has received a $244,479 grant under the IRS Qualified Therapeutic Discovery Project Program. The grant is to advance the development of Angelica's lead drug candidate, Angeloxin, a fusion toxin consisting of deimmunized Diphtheria toxin (DT) fused to Interleukin-2 (IL2).  

The Qualified Therapeutic Discovery Project Program was part of the healthcare reform legislation enacted in March of this year and established a one-time pool of $1 billion for grants to small biotech companies developing novel therapeutics which show potential to, among other things, result in new therapies that either treat areas of unmet medical need, or prevent, detect, or treat chronic or acute diseases and conditions or significantly advance the goal of curing cancer.  

Angelica has collaborated with Antitope, Ltd. (Cambridge, UK) to remove the T cell epitopes from Diphtheria toxin while retaining its cytotoxic potency.  Angeloxin, currently in preclinical development, is the most advanced drug candidate derived from Angelica's technology platform.  It promises to be an advance over Ontak®, currently marketed for the treatment of cutaneous T cell lymphoma and with reports of efficacy in other cancers as well, including peripheral T cell lymphoma and melanoma.

Geoff Davis, CEO of Angelica, said, "We are very pleased to see Angeloxin and the underlying technology platform recognized by this award.  We anticipate that our technology will constitute a significant advance in enabling repeated administration of highly potent and targeted drugs, even to immunocompetent patients, primarily for the treatment of cancer."

About Angelica Therapeutics, Inc. (

SOURCE Angelica Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
2. Osseon® Therapeutics Names Gary Coughlen, CPA as New Chief Financial Officer
3. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
4. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
5. Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
6. Halozyme Therapeutics Realigns Management
7. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
8. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
9. Nile Therapeutics Reports 2010 Third Quarter Financial Results
10. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. ImmunGenes Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... solutions for cardiovascular applications, today announced that they have entered ... will commence a tender offer to acquire all of the ... share, or a total equity purchase price of USD 1 ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... The AXA Research Fund closed out its first year ... than Euro 13 million to various European research institutions.The purpose ... of major risks in the world by supporting cutting edge ... Euro 100 million over five years, making it a major ...
... Research features from Mayo ClinicROCHESTER, Minn., March 23 ... of Discovery,s Edge, Mayo Clinic,s research magazine. You ... often as you wish. Reprinting is allowed with ... as your editorial policies permit: Visit http://discoverysedge.mayo.edu ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:12/20/2014)... -- The holidays can be anything but joyous for ... scented candles and other allergy triggers. "The dust ... been packed away in dank basements or dusty attics ... Dr. Rachna Shah, an affiliate faculty member at Loyola ... news release. Shah, who is also an allergist ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... 20, 2014 The Twin Cities DI ... event in the nation! Over 250 financial professionals come ... information on the industry, get motivated to protect their ... people facing and overcoming the challenges of disability. , ... the nation came together to attend The 13th Annual ...
(Date:12/19/2014)... December 20, 2014 Sweetdressy.com , ... has introduced its newest selection of cheap prom dresses ... very popular in the world and clients can buy ... Meanwhile, these prom dresses feature cool cuts and delicate ... now, targeting the middle-end market. Discount shipping costs are ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 SuperCloset ... 5x5 SuperClone Rooms. SuperCloset continues to offer indoor growers ... Pair one of the new SuperClone Rooms with the ... perpetual, and turnkey indoor hydroponic grow room setup. , ... the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2
... There are now 75 clinical trials and 11 systematic reviews ... is slowing. How will we ever cope?, ask Hilda Bastian, ... PLoS Medicine , who also decry the continued poor quality ... growth of reviews of evidence, the authors recommend that we ...
... PORTLAND, Ore - Research conducted at Oregon Health & ... debate about the risks associated with administering a specific ... is published in the current edition of Cell ... led by institute director Jay Nelson, Ph.D., studies human ...
... Ill. September 21, 2010 Researchers from Italy ... follow-up showing that the placement of multiple endoscopic stents ... with a low rate of stricture recurrence after this ... can be safely and successfully retreated endoscopically. The study ...
... resource guide for internists on the health care reform ... Affordable Care Act (PPACA), was released today by the ... Guide to Understanding Health System Reform was developed by ... significant player in helping to shape the health care ...
... HealthDay Reporter , TUESDAY, Sept. 21 (HealthDay News) ... the blood thinner Plavix with proton-pump inhibitors like Nexium, ... Plavix,s effectiveness. "We looked into this highly debated ... researcher Dr. Mette Charlot from the department of cardiology ...
... One hundred and sixty-six years after Samuel Morse used ... opening up a whole new world of communication, Indiana ... use a potentially equally revolutionary tool, the Nationwide Health ... U.S. Centers for Disease Control and Prevention (CDC). ...
Cached Medicine News:Health News:OHSU research suggests compound administered during some bone marrow transplants elevates risks 2Health News:Results of the placement of multiple endoscopic stents for postoperative biliary strictures remains excellent after long-term follow-up 2Health News:Results of the placement of multiple endoscopic stents for postoperative biliary strictures remains excellent after long-term follow-up 3Health News:Results of the placement of multiple endoscopic stents for postoperative biliary strictures remains excellent after long-term follow-up 4Health News:Updated resource guide for internists released by ACP 2Health News:Plavix, Heartburn Drug Safe to Take Together: Study 2Health News:Nationwide Health Information Network now carries public health data 2Health News:Nationwide Health Information Network now carries public health data 3
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source....
The IVR-Optical Tracking system is engineered for easy calibration. This procedure can be done within five minutes by trained personnel, and is the only calibration required....
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)...
Penfield Dissector #2...
Medicine Products: